Summary of Workgroup Meeting on Use of Family History Information in Pediatric Primary Care and Public Health
暂无分享,去创建一个
[1] Illiam,et al. SCREENING OF INFANTS AND MORTALITY DUE TO NEUROBLASTOMA , 2022 .
[2] D. Freedman,et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. , 1986, The New England journal of medicine.
[3] A. Folsom,et al. Accuracy of proband reported family history: The NHLBI Family Heart Study (FHS) , 1999, Genetic epidemiology.
[4] C. D. de Moor,et al. Skin Cancer Prevention Counseling and Clinical Practices of Pediatricians , 2003, Pediatric dermatology.
[5] N. Obuchowski,et al. Occult intracranial aneurysms in polycystic kidney disease: screening with MR angiography. , 1994, Radiology.
[6] Argyrios Ziogas,et al. Validation of family history data in cancer family registries. , 2003, American journal of preventive medicine.
[7] M. Province,et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). , 2001, The American journal of cardiology.
[8] Muin J Khoury,et al. Can family history be used as a tool for public health and preventive medicine? , 2002, Genetics in Medicine.
[9] G. Forbes,et al. Cranial computed tomography and magnetic resonance imaging in autosomal dominant polycystic kidney disease. , 1990, Journal of the American Society of Nephrology : JASN.
[10] R W Sanson-Fisher,et al. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. , 1999, American journal of preventive medicine.
[11] E. Levy,et al. Usefulness of the American Academy of Pediatrics recommendations for identifying youths with hypercholesterolemia. , 2004, Pediatrics.
[12] D. Wiebers,et al. Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. , 1993, Journal of the American Society of Nephrology : JASN.
[13] Gerald S. Berenson,et al. Autopsy Studies in United States Children and Adolescents a , 1991 .
[14] M. Rewers,et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). , 2004, The Journal of clinical endocrinology and metabolism.
[15] G. Mensah,et al. Serum Total Cholesterol Concentrations and Awareness, Treatment, and Control of Hypercholesterolemia Among US Adults: Findings From the National Health and Nutrition Examination Survey, 1999 to 2000 , 2003, Circulation.
[16] Kakoli Roy,et al. Measuring the Public's Health , 2006, Public health reports.
[17] Dana C Crawford,et al. FMR1 and the fragile X syndrome: Human genome epidemiology review , 2001, Genetics in Medicine.
[18] Ncep Expert Panel on Blood Cholesterol Levels in Childr Adolescents. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. , 1992, Pediatrics.
[19] Margaret Thorogood,et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia , 2002, BMJ : British Medical Journal.
[20] J. Murray,et al. Maternal interview reports of family history of birth defects: evaluation from a population-based case-control study of orofacial clefts. , 1997, American journal of medical genetics.
[21] S. Andersen. [Familial hypercholesterolemia in children]. , 1996, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[22] M. Mennuti,et al. Lights! Camera! Action! , 2001, Obstetrics and gynecology.
[23] S. Sherman,et al. Premature ovarian failure in the fragile X syndrome. , 2000, American journal of medical genetics.
[24] R. Bennett. The Practical Guide to the Genetic Family History , 1999 .
[25] N. Stone,et al. Management of lipids in clinical practice , 1997 .
[26] J. Kastelein,et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. , 2002, Journal of the American College of Cardiology.
[27] Asad A. Rizvi,et al. Hypertrophic cardiomyopathy: Who plays and who sits , 2002, Current sports medicine reports.
[29] D. Illingworth,et al. Lipoproteins in Health and Diseases , 1999 .
[30] M. Khoury,et al. Quantifying the health benefits of genetic tests: The importance of a population perspective , 2006, Genetics in Medicine.
[31] Muin J Khoury,et al. Research priorities for evaluating family history in the prevention of common chronic diseases. , 2003, American journal of preventive medicine.
[32] C. M. Sperberg-McQueen,et al. Extensible Markup Language (XML) , 1997, World Wide Web J..
[33] R. G. Walker,et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 , 1994, The Lancet.
[34] Ann M. Johnson,et al. Attitudes of at-risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. , 1990, American journal of medical genetics.
[35] Ann M. Johnson,et al. Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] D. Bowen,et al. Paternal relatives and family history of breast cancer. , 2006, American journal of preventive medicine.
[37] T. Pearson,et al. Challenges to implementing the current pediatric cholesterol screening guidelines into practice. , 1994, Pediatrics.
[38] Ronald M. Lauer,et al. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: executive summary. National Heart, Lung and Blood Institute, National Institutes of Health. , 1991, Archives of internal medicine.
[39] G. Berenson,et al. Autopsy studies in United States children and adolescents. Relationship of risk factors to atherosclerotic lesions. , 1991, Annals of the New York Academy of Sciences.